Form 4 for BIAF bioAffinity Technologies, Inc.
Accepted 2022-11-22 00:00:00 ET · period of report 2022-08-31 · accession 0001493152-22-033283 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-22 | 2022-09-06 | BIAF | Zannes Maria | Pres, CEO, Dir | C - Cnv Deriv | $4.20 | +23.7K | 43.6K | +119% | +$99.4K |
| D | 2022-11-22 | 2022-11-17 | BIAF | Zannes Maria | Pres, CEO, Dir | A - Grant | $0.00 | +18.1K | 61.7K | +42% | $0 |
| D | 2022-11-22 | 2022-08-31 | BIAF | Zannes Maria | Pres, CEO, Dir | P - Purchase | — | +16.3K | 19.9K | +457% | — |
| D | 2022-11-22 | 2022-09-06 | BIAF | Zannes Maria | Pres, CEO, Dir | A - Grant | — | 0 | 23.6K | New | — |
| DM | 2022-11-22 | 2022-08-31 | BIAF | Zannes Maria | Pres, CEO, Dir | P - Purchase | — | +32.7K | 16.3K | New | — |
| D | 2022-11-22 | 2022-09-06 | BIAF | Zannes Maria | Pres, CEO, Dir | C - Cnv Deriv | $0.00 | -23.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-06 | C | A | 23,672 | $4.20 | 43,569 | D | — | — | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F3) In connection with the IPO closing on September 6, 2022, the $99,423.12 of outstanding principal and accrued but unpaid interest of Ms. Zannes's unsecured convertible promissory note, dated August 11, 2022, automatically converted into 23,672 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis). |
| 2 | Common | Common Stock | 2022-11-17 | A | A | 18,099 | $0.00 | 61,668 | D | — | — | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F5) Represents a grant from the Issuer to Ms. Zannes of 18,099 restricted shares of Common Stock on November 17, 2022 under the Issuer's 2014 Equity Incentive Plan. The restricted stock will begin vesting on December 17, 2022 in 12 monthly installments, the first 11 of which will be of 1,508 shares of Common Stock and the last of which will be of the remaining 1,511 shares of Common Stock, subject to Ms. Zannes's continuous service to the Issuer through each vesting date. |
| 3 | Common | Common Stock | 2022-08-31 | P | A | 16,326 | — | 19,897 | D | — | — | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F2) The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. |
| 4 | Derivative | Warrants (right to buy) | 2022-09-06 | A | A | — | — | 23,571 | D | $6.13 · 2022-09-06 to 2027-08-11 | 23,571 Common Stock | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F4) Represents a right to purchase 23,571 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Ms. Zannes on August 11, 2022 as consideration for funds Ms. Zannes paid to the Issuer for her unsecured convertible promissory note, dated August 11, 2022. |
| 5 | Derivative | Warrants (right to buy) | 2022-08-31 | P | A | 16,326 | — | 16,326 | D | $7.35 · 2022-08-31 to 2027-08-31 | 16,326 Common Stock | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F2) The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. |
| 6 | Derivative | Non-tradeable Warrants (right to buy) | 2022-08-31 | P | A | 16,326 | — | 16,326 | D | $7.66 · 2022-08-31 to 2027-08-31 | 16,326 Common Stock | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F2) The reported securities are included within 16,326 Units purchased by Ms. Zannes for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. |
| 7 | Derivative | Unsecured Convertible Promissory Note | 2022-09-06 | C | D | 23,571 | $0.00 | 0 | D | $4.20 · 2022-09-06 to 2022-10-31 | 23,672 Common Stock | (F1) The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). (F3) In connection with the IPO closing on September 6, 2022, the $99,423.12 of outstanding principal and accrued but unpaid interest of Ms. Zannes's unsecured convertible promissory note, dated August 11, 2022, automatically converted into 23,672 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis). |